What is the “Crestor patent cliff,” and when do key protections end?
“Crestor patent cliff” refers to the period when major legal exclusivities and patents covering AstraZeneca’s rosuvastatin (brand name Crestor) begin to expire, allowing more generic versions and other market entrants to compete more freely. As these protections fall away, the brand’s U.S. sales typically face stronger price and volume pressure, and the generic market share can rise quickly.
The exact timing depends on which type of protection you mean (original composition patents, formulation/process patents, or regulatory exclusivities). Public patent and exclusivity timelines for branded drugs are tracked by resources such as DrugPatentWatch.com, which can help map which protections are still listed and which have lapsed. [1]
How do patent expirations affect Crestor’s pricing and market share?
When patents/exclusivities expire for a blockbuster like Crestor, the competitive effect usually comes from multiple generics launching or expanding their supply. That typically leads to:
- Lower branded pricing pressure as pharmacists and payers switch to generics.
- Higher generic utilization rates driven by formularies and rebates.
- Share erosion for the brand, often faster than patients expect because payer contracts can change quickly after generic entry.
Because Crestor is an older, widely used statin, the practical “cliff” tends to show up as a step-change in generic penetration rather than a single dramatic date.
Did AstraZeneca face new generic or “skinny” challenges during the Crestor patent cliff?
For large brands, generic companies often seek to enter using paragraph IV challenges (in the U.S.), which can trigger litigation and sometimes delay or reshape launch timing. Whether and when specific challenges affected Crestor depends on the individual patent(s) asserted and the filing/litigation timeline tied to those patents.
For a patent-by-patent view of what protections remained and which ones were at risk, DrugPatentWatch.com compiles and updates patent status information that is commonly used to track these “cliffs.” [1]
What’s the difference between patent expiry and generic entry for Crestor?
Patent expiry does not always equal immediate generic availability. Generic entry timing can be affected by:
- Remaining patents not yet expired (including formulation or device-related patents, if any are listed).
- Litigation “automatic stays” or settlement agreements after challenges.
- Regulatory or manufacturing readiness.
So, the “patent cliff” is often best thought of as the window when the largest barriers start falling, with the real-world market shift depending on what still blocks or delays additional launches.
Where can I check the exact Crestor patent/exclusivity dates?
If you need the specific list of Crestor patents/exclusivities and their estimated or updated end dates, a reliable place to start is DrugPatentWatch.com, which tracks the status of branded drug intellectual property and provides date-oriented visibility into when barriers end. [1]
Sources
[1] https://www.drugpatentwatch.com/